Evidence map›Paper›PMID 37101538›Full record

ArticleProceedings of SPIE--the International Society for Optical Engineering

Comparison of surface dose during whole breast radiation therapy on Halcyon and TrueBeam using Cherenkov imaging.

Daniel A Alexander, Olivia Certa, Allison Haertter, Taoran Li, Neil Taunk, Timothy C Zhu

Open access · greenAbstract read
In one paragraph

Article in Proceedings of SPIE--the International Society for Optical Engineering. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Daniel A AlexanderDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104.
Olivia CertaDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104.
Allison HaertterDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104.
Taoran LiDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104.
Neil TaunkDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104.
Timothy C ZhuDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104.
California University of Pennsylvania · USUniversity of Pennsylvania · US

Funding

Cherenkov imaging incorporating 3D surface imaging for TSETR01CA274411 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ZHU, TIMOTHY C. · 2022 to 2025
$2.1M
Cherenkov imaging of Total Skin Electron Therapy (TSET)R21CA239127 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ZHU, TIMOTHY C. · 2020 to 2021
$386k
NCI NIH HHS R01 CA274411NCI NIH HHS R21 CA239127
6 · The paper itself

Abstract

The emergence of the Halcyon linear accelerator has allowed for increased patient throughput and improved treatment times for common treatment sites in radiation oncology. However, it has been shown that this can lead to increased surface dose in sites like breast cancer compared with treatments on conventional machines with flattened radiation beams. Cherenkov imaging can be used to estimate surface dose by detection of Cherenkov photons emitted in proportion to energy deposition from high energy electrons in tissue. Phantom studies were performed with both square beams in reference conditions and with clinical treatments, and dosimeter readings and Cherenkov images report higher surface dose (25% for flat phantom entrance dose, 5.9% for breast phantom treatment) from Halcyon beam deliveries than for equivalent deliveries from a TrueBeam linac. Additionally, the first Cherenkov images of a patient treated with Halcyon were acquired, and superficial dose was estimated.

Indexed as

Cherenkovin vivo dosimetryoptical imagingradiation therapysurface dose

Identifiers

PMID37101538
PMCPMC10128868
OpenAlexW4323306941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.